Comparing Revenue Performance: Teva Pharmaceutical Industries Limited or Arrowhead Pharmaceuticals, Inc.?

Teva vs. Arrowhead: A Decade of Revenue Trends

__timestampArrowhead Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201417500020272000000
Thursday, January 1, 201538200019652000000
Friday, January 1, 201615833321903000000
Sunday, January 1, 20173140770922385000000
Monday, January 1, 20181614232118854000000
Tuesday, January 1, 201916879557716887000000
Wednesday, January 1, 20208799206616658000000
Friday, January 1, 202113828700015878000000
Saturday, January 1, 202224323100014925000000
Sunday, January 1, 202324073500015846000000
Monday, January 1, 2024355100016544000000
Loading chart...

Unleashing insights

Revenue Showdown: Teva vs. Arrowhead

In the dynamic world of pharmaceuticals, revenue performance is a key indicator of a company's market position and growth potential. This chart provides a fascinating comparison between Teva Pharmaceutical Industries Limited and Arrowhead Pharmaceuticals, Inc. over the past decade.

A Decade of Revenue Trends

From 2014 to 2023, Teva consistently outperformed Arrowhead, with revenues peaking at approximately $22 billion in 2017. However, Teva's revenue has seen a gradual decline, dropping to around $15 billion by 2023. In contrast, Arrowhead, though starting from a modest base, has shown impressive growth, with revenues increasing by over 1,300% from 2014 to 2023.

Insights and Implications

While Teva's revenue remains significantly higher, Arrowhead's rapid growth trajectory suggests a promising future. Investors and industry analysts should watch these trends closely, as they reflect broader shifts in the pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025